Mounjaro and Zepbound are the same drug: both are tirzepatide, made by Eli Lilly, at the same doses. The real difference is what each is approved to treat. Mounjaro is approved for type 2 diabetes, and Zepbound is approved for chronic weight management and, more recently, obstructive sleep apnea. That single distinction drives everything that follows, from which one your prescriber writes to what your insurance will pay and what a cash price looks like.
If it is the same molecule, why two names?
Tirzepatide is a single-molecule agonist that acts at both the GIP and GLP-1 receptors, a dual mechanism described in the pharmacology literature on GLP-1 and dual GIP/GLP-1 receptor agonists. Lilly took that one molecule through two separate approval tracks. Mounjaro cleared first for blood sugar control in type 2 diabetes. Zepbound followed for weight management, backed by the obesity trial program.
Two brands for one molecule is not unusual. A drugmaker studies a compound for a specific condition, and the label reflects the population that was studied. The prescribing information for each brand carries its own approved uses, dosing, and warnings, which is why the Mounjaro label and the Zepbound label read differently even though the syringe contents match.
Do the doses actually differ?
No. Both come as single-dose pens or vials in the same strengths: 2.5, 5, 7.5, 10, 12.5, and 15 mg once weekly. The recommended starting dose and the step-up schedule are identical because it is the same drug being titrated the same way. A patient moving between the two for coverage reasons is not changing the medication in any pharmacological sense.
That matters because people sometimes assume the weight-loss version is somehow stronger or formulated differently. It is not. The clinical separation is regulatory and administrative, not chemical.
Which version has the weight-loss evidence?
The obesity data belongs to tirzepatide as a molecule, and it is substantial. In SURMOUNT-1, published in 2022, adults with obesity and without diabetes lost an average of roughly 15 to 21 percent of body weight across doses over 72 weeks, results reported in the trial on tirzepatide once weekly for the treatment of obesity. SURMOUNT-4 looked at what happens after the initial phase, and its finding on continued treatment for maintenance of weight reduction was blunt: people who switched to placebo regained a large share of what they had lost, while those who stayed on tirzepatide held their loss. That is a strong argument that this is chronic therapy, not a short course.
The evidence extends further. SURMOUNT-CN confirmed comparable weight reduction in a study of Chinese adults with obesity, and a separate trial found tirzepatide reduced events in people with obstructive sleep apnea and obesity, which is the basis for that newer Zepbound indication. A 2024 head-to-head comparing semaglutide and tirzepatide for weight loss reported greater average loss with tirzepatide. All of that evidence studied the molecule; Zepbound is simply the brand approved to sell it for weight management.
How does the name change what you pay?
This is where the two names stop being interchangeable. Insurers cover drugs by indication. A plan may cover Mounjaro for a member with a type 2 diabetes diagnosis and refuse Zepbound for the same person if it excludes anti-obesity medication as a category. The reverse also happens. The brand your prescriber selects has to match your diagnosis and your plan’s rules, which is often the deciding factor in what reaches you and at what price.
| Factor | Mounjaro | Zepbound |
|---|---|---|
| Approved use | Type 2 diabetes | Chronic weight management and obstructive sleep apnea |
| Active drug | Tirzepatide | Tirzepatide |
| Dose range | 2.5 to 15 mg weekly | 2.5 to 15 mg weekly |
| Typical coverage trigger | Diabetes diagnosis | Weight or obstructive sleep apnea criteria |
| Self-pay program | Available from the maker | Available from the maker |
What are the routes when a plan says no?
People without qualifying coverage generally have three paths. First, the manufacturer’s savings card, which mostly helps those who already have commercial insurance covering the drug and typically excludes Medicare and Medicaid. Second, the maker’s cash self-pay program, which sells brand tirzepatide vials below list to people paying out of pocket, with conditions on refill timing and dose. Third, compounded tirzepatide from a compounding pharmacy.
Compounded tirzepatide is not an FDA-approved product. It is prepared by a pharmacy rather than manufactured under an approved application, and it has not been through the process that generated the trial evidence above. What it usually offers instead is a predictable flat monthly price with a prescriber in the loop. Some supervised telehealth practices publish that pricing openly, and a resource explaining the difference between Mounjaro and Zepbound can help set expectations before a consult, alongside the direct manufacturer options and services like Ro, Hims and Hers, and LillyDirect. FormBlends is one physician-supervised route among those, not a shortcut around the approval question.
The honest read is that the brand-versus-brand question dissolves once you are paying cash for the molecule. At that point what matters is the source, the supervision, and the sustainable monthly cost, not whether the label on the approved product says Mounjaro or Zepbound.
Is asking for one brand over the other worth it?
Only when it matches your diagnosis and your plan. Asking a prescriber to write Mounjaro for weight loss alone, hoping to game coverage, is off-label prescribing and increasingly gets flagged by both insurers and savings programs. It rarely delivers the savings people imagine, and it can create problems with prior authorization. The better move is to have the prescriber write for the approved use that fits, then work the coverage or self-pay route that goes with it.
If the goal is weight management and the plan excludes that category, switching brand names will not change the answer. The category exclusion applies to tirzepatide for weight loss regardless of what it is called.
Key takeaways
- Mounjaro and Zepbound are both tirzepatide at the same doses; the difference is approved use.
- Mounjaro is approved for type 2 diabetes, Zepbound for weight management and obstructive sleep apnea.
- Insurance covers by indication, so the brand must match your diagnosis and plan rules.
- Compounded tirzepatide is not FDA-approved; it trades trial-backed assurance for a predictable cash price.
- Asking for one brand to dodge coverage rules rarely works and can stall approval.
See also: Where to Buy TB-500 Safely in 2026
Frequently asked questions
Are Mounjaro and Zepbound the same drug?
Yes, both are tirzepatide, the same active molecule from the same maker. They differ in their FDA-approved use: Mounjaro is approved for type 2 diabetes and Zepbound is approved for chronic weight management and obstructive sleep apnea.
Can I ask for Mounjaro instead of Zepbound to save money?
A prescriber writes for the approval that fits your diagnosis. Prescribing Mounjaro for weight loss alone is off-label, and many plans and savings programs check that the use matches the label, so the swap often does not produce the savings people expect.
Do the two versions come in different doses?
The tirzepatide doses are the same across both, from 2.5 mg up to 15 mg weekly. The titration schedule the label describes is also the same, because it is the same drug.
Is compounded tirzepatide the same as Mounjaro or Zepbound?
No. Compounded tirzepatide is prepared by a compounding pharmacy and is not an FDA-approved product. It may contain the same molecule, but it has not been through the approval process behind the brand trial evidence.
Which one has the weight-loss trial data?
The obesity trials, including SURMOUNT-1, studied tirzepatide, the molecule in both products. Zepbound is the brand approved on the strength of that weight-management evidence.
